SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-20-000058
Filing Date
2020-11-10
Accepted
2020-11-10 17:01:51
Documents
41
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ctic-20200930.htm   iXBRL 10-Q 1217212
2 EX-10.1 ex101ctibiopharmacorp2.htm EX-10.1 100598
3 EX-31.1 ex311-ceo302q3fy20.htm EX-31.1 13885
4 EX-31.2 ex312-cfo302q3fy20.htm EX-31.2 15320
5 EX-32 ex32-ceocfo906q3fy20.htm EX-32 15468
  Complete submission text file 0000891293-20-000058.txt   4103297

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20200930.xsd EX-101.SCH 21089
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20200930_cal.xml EX-101.CAL 66156
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20200930_def.xml EX-101.DEF 114036
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20200930_lab.xml EX-101.LAB 316436
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20200930_pre.xml EX-101.PRE 192873
11 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20200930_htm.xml XML 488881
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 201301990
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences